Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy

Gao, Lan, Xia, Li, Pan, Song-Qing, Xiong, Tao and Li, Shu-Chuen 2015, Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy, Epilepsy research, vol. 110, pp. 146-156, doi: 10.1016/j.eplepsyres.2014.12.001.

Attached Files
Name Description MIMEType Size Downloads

Title Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy
Author(s) Gao, LanORCID iD for Gao, Lan orcid.org/0000-0001-9734-1140
Xia, Li
Pan, Song-Qing
Xiong, Tao
Li, Shu-Chuen
Journal name Epilepsy research
Volume number 110
Start page 146
End page 156
Total pages 11
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2015-02
ISSN 1872-6844
Keyword(s) China
Cost of illness
Summary OBJECTIVES: We aimed to gauge the burden of epilepsy in China from a societal perspective by estimating the direct, indirect and intangible costs. METHODS: Patients with epilepsy and controls were enrolled from two tertiary hospitals in China. Patients were asked to complete a Cost-of-Illness (COI), Willingness-to-Pay (WTP) questionnaires, two utility elicitation instruments and Mini Mental State Examination (MMSE). Healthy controls only completed WTP questionnaire, and utility instruments. Univariate analyses were performed to investigate the differences in cost on the basis of different variables, while multivariate analysis was undertaken to explore the predictors of cost/cost component. RESULTS: In total, 141 epilepsy patients and 323 healthy controls were recruited. The median total cost, direct cost and indirect cost due to epilepsy were US$949.29, 501.34 and 276.72, respectively. Particularly, cost of anti-epileptic drugs (AEDs) (US$394.53) followed by cost of investigations (US$59.34), cost of inpatient and outpatient care (US$9.62) accounted for the majority of the direct medical costs. While patients' (US$103.77) and caregivers' productivity costs (US$103.77) constituted the major component of indirect cost. The intangible costs in terms of WTP value (US$266.07 vs. 88.22) and utility (EQ-5D, 0.828 vs. 0.923; QWB-SA, 0.657 vs. 0.802) were both substantially higher compared to the healthy subjects. CONCLUSIONS: Epilepsy is a cost intensive disease in China. According to the prognostic groups, drug-resistant epilepsy generated the highest total cost whereas patients in seizure remission had the lowest cost. AED is the most costly component of direct medical cost probably due to 83% of patients being treated by new generation of AEDs.
Language eng
DOI 10.1016/j.eplepsyres.2014.12.001
Field of Research 1103 Clinical Sciences
111799 Public Health and Health Services not elsewhere classified
Socio Economic Objective 920299 Health and Support Services not elsewhere classified
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2015, Elsevier
Persistent URL http://hdl.handle.net/10536/DRO/DU:30075442

Document type: Journal Article
Collections: Faculty of Health
School of Health and Social Development
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 29 times in TR Web of Science
Scopus Citation Count Cited 27 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 496 Abstract Views, 3 File Downloads  -  Detailed Statistics
Created: Wed, 11 Nov 2015, 09:33:10 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.